Research analysts at StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Free Report) in a research note issued on Monday. The brokerage set a “hold” rating on the stock.
Can-Fite BioPharma Trading Up 1.5 %
NYSE:CANF opened at $2.01 on Monday. The stock has a market capitalization of $7.12 million, a PE ratio of -1.10 and a beta of 1.53. The firm’s 50 day moving average is $2.16 and its 200 day moving average is $2.12. Can-Fite BioPharma has a 12 month low of $1.68 and a 12 month high of $3.33.
Can-Fite BioPharma (NYSE:CANF – Get Free Report) last issued its earnings results on Thursday, March 28th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.20 million. Research analysts predict that Can-Fite BioPharma will post -0.03 earnings per share for the current year.
Institutional Inflows and Outflows
Can-Fite BioPharma Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Further Reading
- Five stocks we like better than Can-Fite BioPharma
- Where Do I Find 52-Week Highs and Lows?
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Investing In Automotive Stocks
- Lockheed Martin Stock Aims for a Fresh All-Time High
- The Most Important Warren Buffett Stock for Investors: His Own
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.